JP6662312B2 - Solid composition - Google Patents
Solid composition Download PDFInfo
- Publication number
- JP6662312B2 JP6662312B2 JP2017004042A JP2017004042A JP6662312B2 JP 6662312 B2 JP6662312 B2 JP 6662312B2 JP 2017004042 A JP2017004042 A JP 2017004042A JP 2017004042 A JP2017004042 A JP 2017004042A JP 6662312 B2 JP6662312 B2 JP 6662312B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- solid composition
- ondi
- mass
- ondi extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008247 solid mixture Substances 0.000 title claims description 32
- 239000000284 extract Substances 0.000 claims description 47
- 238000002845 discoloration Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 229950008138 carmellose Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 13
- 239000007884 disintegrant Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001080798 Polygala tenuifolia Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
本発明は、オンジエキスを含有する固形組成物に関する。 The present invention relates to a solid composition containing ondi extract.
オンジエキスはヒメハギ科イトヒメハギの根から得られものであり、去痰、鎮静、滋養強壮、精神安定、記憶力改善等の目的で用いられる。オンジエキスを含有する固形組成物としては、漢方の加味帰脾湯、人参養栄湯、加味温胆湯、帰脾湯等が知られるものの、いずれもオンジエキス以外に複数の生薬エキスが含まれるため、オンジエキスの含有量は少ない。また、漢方としてオンジ単味製品が市販されているが、カプセル剤であるため服用しにくいものであった。
今まで、オンジエキスの効果が十分に発揮されるオンジエキスを高濃度含有する固形組成物について、製剤化の検討はなされていない。
本発明者らは、オンジエキスを高濃度含む組成物を製造したところ、経時的に変色するという課題に直面した。一般的に、変色は商品価値の低下や服用性を悪化させる傾向があり、好ましくない。
生薬エキスの色の変化を抑制する手法としては、ポリ酢酸ビニルの配合が報告されているが（特許文献１）、この方法は噴霧・乾燥といった煩雑な製造工程が必要である。また、２種の吸着剤を配合して抑制する方法が報告されているが（特許文献２）、その効果は十分ではない。
Ondi extract is obtained from the roots of the family Himehagi, and is used for the purpose of expectoration, sedation, nourishing tonic, mental stability, memory improvement and the like. As a solid composition containing Onji extract, Kampo Kikyou-to, Kaminyo-yoei-to, Kami-onbetsu-to, Ki-koku-to, etc. are known, but all contain multiple crude drug extracts other than Onji extract, The content of ondi extract is small. Onji plain products are commercially available as Kampo medicines, but are difficult to take because they are capsules.
Until now, there has been no study on formulation of a solid composition containing a high concentration of ondi extract in which the effect of ondi extract is sufficiently exhibited.
The present inventors have faced the problem of discoloring over time when producing a composition containing a high concentration of ondi extract. In general, discoloration tends to lower the commercial value and worsen the ingestibility, which is not preferable.
As a technique for suppressing a change in the color of the crude drug extract, blending of polyvinyl acetate has been reported (Patent Document 1), but this method requires a complicated manufacturing process such as spraying and drying. In addition, a method has been reported in which two types of adsorbents are mixed and suppressed (Patent Document 2), but the effect is not sufficient.
本発明の目的は、経時的な色の変化を抑制した、オンジエキスを含有する固形組成物を提供することにある。 An object of the present invention is to provide a solid composition containing ondi extract, which suppresses a change in color over time.
本発明者らは、上記課題を解決するべく鋭意検討した結果、オンジエキスと特定のセルロース系崩壊剤を含有する固形組成物は、経時的な変色が抑制されることを見出し、本発明を完成するに至った。 The present inventors have conducted intensive studies to solve the above problems, and as a result, have found that a solid composition containing ondi extract and a specific cellulosic disintegrant suppresses discoloration over time, and completes the present invention. Reached.
すなわち、本発明は、
（１）オンジエキス、及びクロスカルメロースナトリウム、カルメロースカルシウム、及び低置換度ヒドロキシプロピルセルロースからなる群から選ばれる少なくとも１種のセルロース系崩壊剤を含有し、オンジエキスの含有量が固形組成物全体に対し１０質量％以上であることを特徴とする固形組成物、
（２）さらに、結晶セルロース及び／又は軽質無水ケイ酸を含む、（１）に記載の固形組成物、
（３）固形組成物が内服用である、（１）又は（２）に記載の固形製剤、
（４）固形組成物が錠剤、顆粒剤、散剤、チュアブル錠剤、口腔内崩壊錠又はドライシロップ剤である、（１）〜（３）のいずれかに記載の固形組成物、
（５）オンジエキスを含有する固形組成物の変色を抑制するために、クロスカルメロースナトリウム、カルメロースカルシウム、及び低置換度ヒドロキシプロピルセルロースからなる群から選ばれる少なくとも１種のセルロース系崩壊剤を使用する方法、
（６）クロスカルメロースナトリウム、カルメロースカルシウム、及び低置換度ヒドロキシプロピルセルロースからなる群から選ばれる少なくとも１種のセルロース系崩壊剤を添加することによって、オンジエキス含有固形組成物の変色を抑制する方法、
である。
That is, the present invention
(1) The composition contains at least one cellulosic disintegrant selected from the group consisting of ondi extract, croscarmellose sodium, carmellose calcium, and low-substituted hydroxypropylcellulose, and the content of ondi extract in the entire solid composition A solid composition characterized by being 10% by mass or more,
(2) The solid composition according to (1), further comprising microcrystalline cellulose and / or light silicic anhydride.
(3) The solid preparation according to (1) or (2), wherein the solid composition is for internal use.
(4) The solid composition according to any one of (1) to (3), wherein the solid composition is a tablet, granule, powder, chewable tablet, orally disintegrating tablet or dry syrup.
(5) At least one cellulose disintegrant selected from the group consisting of croscarmellose sodium, carmellose calcium, and low-substituted hydroxypropylcellulose is used to suppress discoloration of the solid composition containing the ondi extract. how to,
(6) A method for suppressing discoloration of a solid composition containing ondi extract by adding at least one cellulosic disintegrant selected from the group consisting of croscarmellose sodium, carmellose calcium, and low-substituted hydroxypropylcellulose. ,
It is.
本発明により、長期にわたって変色が抑制されたオンジエキス含有固形組成物の提供が可能となった。 According to the present invention, it has become possible to provide a solid composition containing ondi extract in which discoloration is suppressed for a long period of time.
本発明のオンジエキスは、第１６改正日本薬局方収載のオンジ（ヒメハギ属のイトヒメハギ（Ｐｏｌｙｇａｌａ ｔｅｎｕｉｆｏｌｉａ）の根）から水やエタノール等の有機溶媒により抽出したオンジエキス、又はエキスを粉末化したオンジエキス末等を使用することができる。市販品としては、例えばオンジ乾燥エキス（アルプス薬品工業）、オンジエキス−Ａ（日本粉末薬品）、オンジエキス（常盤植物化学）等を使用できる。 The ondi extract of the present invention is an ondi extract extracted from an ondi (root of Polygala tenuifolia) belonging to the 16th revised Japanese Pharmacopoeia using an organic solvent such as water or ethanol, or an ondi extract powder obtained by powdering the extract. Can be used. As a commercially available product, for example, Onji Dry Extract (Alps Pharmaceutical), Onji Extract-A (Nippon Shokubai), Onji Extract (Tokiwa Plant Chemicals), etc. can be used.
本発明の固形組成物において、オンジエキスの含有量は、固形組成物全体の１０質量％以上であり、好ましくは１４質量％以上、より好ましくは３０質量％以上である。固形組成物中に１０質量％以上配合すると、固形組成物の変色が目立つようになるからである。また上限は９０質量％である。また、原生薬換算で、本発明の固形組成物中に２５０mg以上、好ましくは３３０mg以上、より好ましくは５００mg以上である。 In the solid composition of the present invention, the content of the ondi extract is 10% by mass or more, preferably 14% by mass or more, more preferably 30% by mass or more of the whole solid composition. This is because if the content is 10% by mass or more in the solid composition, the discoloration of the solid composition becomes conspicuous. The upper limit is 90% by mass. In addition, the amount is 250 mg or more, preferably 330 mg or more, more preferably 500 mg or more in the solid composition of the present invention in terms of a crude drug.
本発明の特定のセルロース系崩壊剤とは、クロスカルメロースナトリウム、カルメロースカルシウム又は低置換度ヒドロキシプロピルセルロースを意味する。セルロース系崩壊剤の含有量は、発明の効果の点から、オンジエキス１質量部に対し０．１〜２質量部が好ましく、０．３〜２質量部が更に好ましい。また、本発明の固形組成物全体の３質量％〜９０質量％が好ましく、１０質量％〜７０質量％が更に好ましい。クロスカルメロースナトリウムとしては、粒状のものでも粉末状のものであってもよく、市販品としては、例えばアクジゾル（ワイケイエフ）や、キッコレート（三栄源エフ・エフ・アイ）等が使用できる。カルメロースカルシウムとしては、例えば市販品のカルメロースカルシウム（ニチリン化学）やE.C.G-505（五徳薬品）等が使用できる。低置換度ヒドロキシプロピルセルロースは粒状のものでも粉末状のものであってもよく、市販品としては、例えば市販品のL-HPC-LH21（信越化学工業）等が使用できる。
また、本発明の固形組成物に、さらに結晶セルロース及び／又は軽質無水ケイ酸を配合すると、本発明の変色抑制の効果の点からより好ましいものとなる。結晶セルロースの配合量は、本発明の固形組成物中、１〜７０質量％が好ましい。また、軽質無水ケイ酸の配合量は、本発明の固形組成物中、１〜７０質量％が好ましい。
The specific cellulosic disintegrant of the present invention means croscarmellose sodium, carmellose calcium or low-substituted hydroxypropylcellulose. The content of the cellulosic disintegrant is preferably 0.1 to 2 parts by mass, more preferably 0.3 to 2 parts by mass, per 1 part by mass of the ondi extract from the viewpoint of the effect of the invention. Moreover, 3 mass%-90 mass% of the whole solid composition of this invention is preferable, and 10 mass%-70 mass% is more preferable. Croscarmellose sodium may be in the form of granules or powder, and commercially available products include, for example, Akdizol (YKK) and Kikkolate (San-Eigen FFI). As carmellose calcium, for example, commercially available carmellose calcium (Nichirin Chemical Co., Ltd.), ECG-505 (Gotoku Pharmaceutical Co., Ltd.) and the like can be used. The low-substituted hydroxypropylcellulose may be in a granular form or a powdery form. As a commercially available product, for example, a commercially available product such as L-HPC-LH21 (Shin-Etsu Chemical Co., Ltd.) can be used.
Further, when crystalline cellulose and / or light anhydrous silicic acid is further blended with the solid composition of the present invention, it becomes more preferable from the viewpoint of the effect of suppressing discoloration of the present invention. The compounding amount of the crystalline cellulose is preferably from 1 to 70% by mass in the solid composition of the present invention. The amount of the light anhydrous silicic acid is preferably 1 to 70% by mass in the solid composition of the present invention.
本発明の固形組成物とは、２成分以上の成分により構成される常温で固体状の組成物をいい、例えば、混合することにより得られる粉末、造粒により得られる造粒物、粉末や造粒物を打錠することにより得られる錠剤などを挙げることができる。剤型としては、錠剤、顆粒剤、散剤、チュアブル錠剤、口腔内崩壊錠又はドライシロップ剤等を挙げることができ、特にこれらに限定されるものではない。また、その製造方法は、医薬品の製剤化における一般的な方法で製造することができ、本発明の効果を損なわない範囲で製剤製造時に一般的に配合される成分を適宜配合することができる。オンジエキス及び特定のセルロース系崩壊剤を配合し、必要に応じて他の公知の添加剤、例えば賦形剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、コーティング剤、着色剤、矯味矯臭剤、界面活性剤、可塑剤等を混合して常法により製造することができる。 The solid composition of the present invention refers to a composition which is solid at room temperature and is composed of two or more components. For example, powder obtained by mixing, granulated product obtained by granulation, Tablets obtained by compressing granules can be mentioned. Examples of the dosage form include tablets, granules, powders, chewable tablets, orally disintegrating tablets, and dry syrups, and are not particularly limited thereto. In addition, the production method can be produced by a general method in the preparation of pharmaceuticals, and components generally incorporated in the production of the preparation can be appropriately mixed as long as the effects of the present invention are not impaired. Mix ondi extract and a specific cellulosic disintegrant, and if necessary, other known additives such as excipients, disintegrants, binders, lubricants, antioxidants, coating agents, coloring agents, flavors , A surfactant, a plasticizer and the like can be mixed and manufactured by a conventional method.
以下に実施例及び比較例を挙げ、本説明をさらに詳細に説明するが、本発明は以下の実施例に何ら限定されるものではない。なお、表中の単位はｍｇである。
以下表１に比較例１〜３、及び実施例１〜６の処方を示す。オンジエキス（原生薬換算量５００ｍｇ）と各成分をビニール袋内で混合した後、篩を通してオンジエキス含有粉体を調製した。
Hereinafter, the present description will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples. The unit in the table is mg.
Table 1 below shows the formulations of Comparative Examples 1 to 3 and Examples 1 to 6. After mixing Ondi extract (equivalent amount of crude drug 500 mg) and each component in a plastic bag, the powder containing Ondi extract was prepared through a sieve.
（試験例１）
実施例１〜６及び比較例１〜３について25℃60％RH条件下で24時間静置したのち、２ｇずつガラスビンに入れて密閉し、65℃条件下で３日保存した。保存後の粉体について、それぞれ製造直後品との色差ΔE*(ab)について分光式光度計（SE6000 日本電色工業製）を用いて測定した。結果を、表１及び図１に示す。
(Test Example 1)
Each of Examples 1 to 6 and Comparative Examples 1 to 3 was allowed to stand at 25 ° C. and 60% RH for 24 hours, then placed in a glass bottle, sealed and stored at 65 ° C. for 3 days. For the powder after storage, the color difference ΔE * (ab) from the product immediately after production was measured using a spectrophotometer (SE6000 manufactured by Nippon Denshoku Industries). The results are shown in Table 1 and FIG.
表１及び図１より明らかなように、オンジエキスを含む固形組成物は変色した（比較例１）。本発明のセルロース系崩壊剤を含む実施例１〜６の固形組成物は、デンプン系の崩壊剤であるアルファ化デンプン、部分α化デンプンを配合した比較例２、３の固形組成物と比べて、経時的な色の変化は抑制された。また、軽質無水ケイ酸及び／又は結晶セルロースを配合するとさらに色の変化が抑制された。 As is clear from Table 1 and FIG. 1, the solid composition containing the ondi extract was discolored (Comparative Example 1). The solid compositions of Examples 1 to 6 containing the cellulosic disintegrant of the present invention were compared with the solid compositions of Comparative Examples 2 and 3 in which pregelatinized starch as a starch-based disintegrant and partially pregelatinized starch were blended. The color change over time was suppressed. When light anhydrous silicic acid and / or crystalline cellulose were added, the change in color was further suppressed.
（実施例７）
以下表２に実施例７の処方を示す。オンジエキス（原生薬換算量５００ｍｇ）とオンジエキス以外の成分ａを乳鉢にて混合した後篩顆したものをオンジエキス含有粉体とした。オンジエキス含有粉体に成分ｂを添加後、混合・篩顆したものを打錠用粉末とした。１錠重量341.7 mgとして簡易錠剤成型機（HANDTAB−200；市橋精機社製）で錠剤を製した。
(Example 7)
Table 2 below shows the formulation of Example 7. Ondi extract (produced amount of crude drug: 500 mg) and component a other than ondi extract were mixed in a mortar and then sieved, to obtain a powder containing the ondi extract. After the component b was added to the ondi extract-containing powder, the mixture was mixed and sieved to obtain a tableting powder. A tablet was manufactured using a simple tablet molding machine (HANDTAB-200; manufactured by Ichihashi Seiki Co., Ltd.) with a tablet weight of 341.7 mg.
（試験例２）
実施例７のオンジエキス含有錠剤について25℃60％RH条件下で２４時間静置したのちガラスビンに入れて密閉し、６５℃条件下で３日保存した。保存後の錠剤について、それぞれ製造直後品との色差ΔE*(ab)について分光式光度計（SE6000 日本電色工業製）を用いて測定した。
(Test Example 2)
The ondi extract-containing tablet of Example 7 was allowed to stand at 25 ° C. and 60% RH for 24 hours, then sealed in a glass bottle, and stored at 65 ° C. for 3 days. For the stored tablets, the color difference ΔE * (ab) from each of the tablets immediately after production was measured using a spectrophotometer (SE6000 manufactured by Nippon Denshoku Industries Co., Ltd.).
表２から明らかのように、セルロース系崩壊剤であるクロスカルメロースナトリウムを配合したオンジエキス配合錠剤は経時的色の変化を抑制できた。 As is evident from Table 2, the ondiextract-containing tablet containing croscarmellose sodium, which is a cellulosic disintegrant, was able to suppress the color change over time.
（実施例８〜１１）
以下表３に、実施例８〜１１の処方を示す。オンジエキス（原生薬換算量５００ｍｇ）とオンジエキス以外の成分ａを乳鉢にて混合した後篩顆したものをオンジエキス含有粉体とした。オンジエキス含有粉体に成分ｂを添加後、混合・篩顆したものを打錠用粉末とした。１錠重量341.7 mgとして簡易錠剤成型機（HANDTAB−200；市橋精機社製）で錠剤を製した。
(Examples 8 to 11)
Table 3 below shows the formulations of Examples 8 to 11. Ondi extract (produced amount of crude drug: 500 mg) and component a other than ondi extract were mixed in a mortar and then sieved, to obtain a powder containing the ondi extract. After the component b was added to the ondi extract-containing powder, the mixture was mixed and sieved to obtain a tableting powder. A tablet was manufactured using a simple tablet molding machine (HANDTAB-200; manufactured by Ichihashi Seiki Co., Ltd.) with a tablet weight of 341.7 mg.
（試験例３）
実施例８〜１１のオンジエキス含有錠剤について25℃60％RH条件下で２４時間静置したのちガラスビンに入れて密閉し、６５℃条件下で３日保存した。保存後の錠剤について、それぞれ製造直後品との色差ΔE*(ab)について分光式光度計（SE6000 日本電色工業製）を用いて測定した。
(Test Example 3)
The ondi extract-containing tablets of Examples 8 to 11 were allowed to stand at 25 ° C. and 60% RH for 24 hours, then sealed in a glass bottle, and stored at 65 ° C. for 3 days. For the stored tablets, the color difference ΔE * (ab) from each of the tablets immediately after production was measured using a spectrophotometer (SE6000 manufactured by Nippon Denshoku Industries Co., Ltd.).
本発明により、オンジエキスを高濃度含有していても、経時的な変色が抑制された、商品価値の高いオンジエキス配合の固形組成物の提供が可能となった。 Advantageous Effects of Invention According to the present invention, it has become possible to provide a solid composition containing an ondi extract and having a high commercial value, in which discoloration over time is suppressed even when the ondi extract is contained at a high concentration.
Claims (2)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014246787 | 2014-12-05 | ||
| JP2014246787 | 2014-12-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231564A Division JP6327237B2 (en) | 2014-12-05 | 2015-11-27 | Solid composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017061576A JP2017061576A (en) | 2017-03-30 |
| JP2017061576A5 JP2017061576A5 (en) | 2019-01-10 |
| JP6662312B2 true JP6662312B2 (en) | 2020-03-11 |
Family
ID=56121796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231564A Active JP6327237B2 (en) | 2014-12-05 | 2015-11-27 | Solid composition |
| JP2017004042A Active JP6662312B2 (en) | 2014-12-05 | 2017-01-13 | Solid composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231564A Active JP6327237B2 (en) | 2014-12-05 | 2015-11-27 | Solid composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6327237B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6668706B2 (en) * | 2014-12-12 | 2020-03-18 | 大正製薬株式会社 | Solid composition |
| JP6286383B2 (en) * | 2015-03-27 | 2018-02-28 | 小林製薬株式会社 | Solid pharmaceutical composition |
| JP2017075136A (en) * | 2015-06-08 | 2017-04-20 | ロート製薬株式会社 | Internal composition |
| JP6294943B2 (en) * | 2016-10-28 | 2018-03-14 | 小林製薬株式会社 | Solid pharmaceutical composition |
| JP7235193B2 (en) * | 2017-04-26 | 2023-03-08 | 大正製薬株式会社 | solid composition |
| JP6982290B2 (en) * | 2017-06-15 | 2021-12-17 | 大峰堂薬品工業株式会社 | Solid pharmaceutical formulation for internal use containing Onji extract |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04243832A (en) * | 1991-01-22 | 1992-08-31 | Kanebo Ltd | Treating agent for autoimmune disease |
| JPH05139982A (en) * | 1991-11-26 | 1993-06-08 | Kanebo Ltd | Ischemic encephalopathy improving agent |
| JP4293572B2 (en) * | 1998-06-30 | 2009-07-08 | 株式会社龍角散 | Loxoprofen sodium-containing tablets |
| JP5021210B2 (en) * | 2006-01-16 | 2012-09-05 | エスエス製薬株式会社 | Compression molding |
| JP5989960B2 (en) * | 2010-02-26 | 2016-09-07 | 小林製薬株式会社 | Salacia-containing composition |
| JP5226732B2 (en) * | 2010-05-20 | 2013-07-03 | エスエス製薬株式会社 | Compression molding for hypnosis |
| JP5759113B2 (en) * | 2010-06-16 | 2015-08-05 | 旭化成ケミカルズ株式会社 | Extract powder combination tablets |
| JP6062168B2 (en) * | 2011-07-01 | 2017-01-18 | 武田薬品工業株式会社 | Formulation containing herbal medicine-derived component and method for producing the same |
| JP2013053144A (en) * | 2011-08-09 | 2013-03-21 | Daiichi Sankyo Healthcare Co Ltd | Sedative composition |
| KR20140017976A (en) * | 2012-08-03 | 2014-02-12 | 삼성제약공업주식회사 | Vita hybrid tablet for student and manufacturing method thereof |
| JP2014166994A (en) * | 2013-02-04 | 2014-09-11 | Rohto Pharmaceut Co Ltd | Novel chinese medicine extract formulation |
-
2015
- 2015-11-27 JP JP2015231564A patent/JP6327237B2/en active Active
-
2017
- 2017-01-13 JP JP2017004042A patent/JP6662312B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016108327A (en) | 2016-06-20 |
| JP2017061576A (en) | 2017-03-30 |
| JP6327237B2 (en) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6662312B2 (en) | Solid composition | |
| JP6716940B2 (en) | Extract powder | |
| WO2014038593A2 (en) | Granulated material for tablet that rapidly disintegrates in mouth | |
| JP6286383B2 (en) | Solid pharmaceutical composition | |
| KR20170128323A (en) | Solid preparation containing colorant | |
| JPWO2015115453A1 (en) | Oral rapidly disintegrating composition for solid preparation | |
| JP6701689B2 (en) | Solid composition | |
| KR101640958B1 (en) | Pharmaceutical solid preparation having active ingredients separated by boundary therein | |
| JP2017019869A (en) | Solid pharmaceutical composition | |
| WO2019004447A1 (en) | Pharmaceutical composition | |
| KR20160002177A (en) | Pharmaceutical composition comprising oseltamivir free base | |
| JP2017155061A (en) | Solid pharmaceutical composition | |
| JP2017155058A (en) | Solid pharmaceutical composition | |
| JP2013216701A (en) | Preparation for oral administration | |
| JP6262490B2 (en) | Intraoral rapidly disintegrating tablet composition | |
| JP2016050206A (en) | Pharmaceutical tablet containing levocarnitine | |
| JPWO2017142001A1 (en) | Granules for intraoral rapidly disintegrating tablets | |
| JP2017066133A (en) | Ibuprofen-containing solid preparation with high stability and quick-acting properties | |
| JP6838474B2 (en) | Solid composition | |
| JP2022130003A (en) | Solid preparation containing chinese medicine extract or vegetable herbal medicine extract, and method for producing the same, and method for improving the ease of disintegration of solid preparation | |
| JP6114573B2 (en) | Solid formulation containing loxoprofen sodium and antacid | |
| JP6439503B2 (en) | Solid preparation | |
| Venkateswarlu et al. | Formulation and e valuation of famotidine fast dissolving tablets by direct compression method | |
| JP2017078051A (en) | Pharmaceutical composition | |
| JP6668706B2 (en) | Solid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200114 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200127 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6662312 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |